SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
1.820
-0.130 (-6.67%)
At close: Feb 21, 2025, 4:00 PM
1.760
-0.060 (-3.30%)
After-hours: Feb 21, 2025, 4:57 PM EST
SAB Biotherapeutics Revenue
SAB Biotherapeutics had revenue of $1.51M in the twelve months ending September 30, 2024, down -63.06% year-over-year. In the year 2023, SAB Biotherapeutics had annual revenue of $2.24M, down -90.63%.
Revenue (ttm)
$1.51M
Revenue Growth
-63.06%
P/S Ratio
10.38
Revenue / Employee
$26,539
Employees
57
Market Cap
16.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
Dec 31, 2019 | 3.44M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SABS News
- 22 days ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 25 days ago - Why Is SAB BIO Stock Trading Lower On Tuesday? - Benzinga
- 25 days ago - SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - GlobeNewsWire
- 4 weeks ago - SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy - GlobeNewsWire
- 3 months ago - SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 5 months ago - SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 6 months ago - SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewsWire
- 7 months ago - SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewsWire